United States — Food and Drug Administration & Levi & Korsinsky
11 shared events · Importance 3 · Last updated Aug 18, 2026
Live sentiment trends, interaction importance charts, and action volume tracking available on the
Ergen Dashboard
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration raised safety concerns about the PRC2 inhibitor drug class, specifically regarding potential malignancy risk, which led to the discontinuation of pociredir by Fulcrum Therapeutics.
Levi & Korsinsky: Levi & Korsinsky initiated an investigation into Fulcrum Therapeutics for potential securities fraud, representing shareholders who suffered losses.
Jun 02, 2026 · 6 articles
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration issued safety warnings concerning serious neurological complications in dogs related to Zoetis' Bedinvetmab, contributing to its weakening adoption.
Levi & Korsinsky: Levi & Korsinsky notifies investors in Zoetis Inc. that a class action lawsuit has been filed on behalf of shareholders.
May 18, 2026 · 316 articles
Regulatory
United States — Food and Drug Administration: The FDA's regulatory process for nicotine pouches is central to the investigation; its authorization decisions affect Altria's product pipeline and market position.
Levi & Korsinsky: Levi & Korsinsky is the law firm conducting the investigation, which could lead to a securities class action and generate contingency fees.
Jul 31, 2026 · 6 articles
Business
United States — Food and Drug Administration: The United States — Food and Drug Administration's potential non-approval of Savara Inc.'s MOLBREEVI BLA is a key factor in the alleged securities fraud.
Levi & Korsinsky: Levi & Korsinsky is the law firm initiating and representing investors in the class action securities lawsuit against Savara Inc.
Oct 06, 2025 · 6 articles
Regulatory
United States — Food and Drug Administration: The FDA rejected Replimune's BLA and published briefing documents raising concerns about the data package, triggering the stock drop and subsequent lawsuits. The FDA's actions are central to the event.
Levi & Korsinsky: Levi & Korsinsky filed a securities class action lawsuit against Replimune, representing investors who suffered losses. The firm is seeking lead plaintiff appointments.
Jul 29, 2026 · 65 articles
Regulatory
United States — Food and Drug Administration: Regulator whose briefing documents and advisory committee vote triggered the stock collapse and legal actions.
Levi & Korsinsky: Attorney at Levi & Korsinsky involved in the investigation.
Jul 27, 2026 · 293 articles
Business
Levi & Korsinsky: Levi & Korsinsky is a law firm that has notified investors of a class action securities lawsuit against Coya Therapeutics, alleging securities fraud.
Jun 27, 2025 · 44 articles
Business
Levi & Korsinsky: Levi & Korsinsky is a law firm that has filed a class action securities lawsuit against Replimune Group, Inc. on behalf of investors who suffered losses.
Jul 25, 2025 · 26 articles
ERGEN INTELLIGENCE
Explore this relationship live
Track how United States — Food and Drug Administration and Levi & Korsinsky interact across events, view sentiment trends, and discover connected entities.
Open Dashboard